
StockTalk: How Are ASX medtechs responding to skyrocketing healthcare spending?
InteliCare’s CEO and Managing Director, Jason Waller joins a panel of medtech experts to discuss increased healthcare spending and its impact on the sector.
You are here: Home News & Events
InteliCare’s CEO and Managing Director, Jason Waller joins a panel of medtech experts to discuss increased healthcare spending and its impact on the sector.
Aged care remote monitoring technology company, InteliCare (ASX:ICR), made a spectacular debut on the ASX this week with the shares reaching a peak at 58c.
InteliCare’s hares surged on opening, reaching as high as a 95 per cent increase at 39c, from the IPO price of 20c.
After the first day of trading, InteliCare’s (ASX:ICR) stocks have finished 57.5 per cent higher than the IPO cost.
Watch ABC’s Alan Kohler’s summary of InteliCare’s ASX listing on today’s financial report. “A new listing came on that bounced like tigger!”
Finance News Network listed the telelhealth company, InteliCare (ASX:ICR), as one of the best-performing stocks on its debut.
At-home aged care technology company, InteliCare (ASX:ICR), listed on the ASX on Monday, May 25th and nearly doubled its IPO price on the first day.
Within hours on listing on the ASX, aged care technology company, InteliCare has increased 50 per cent from its listing price.
InteliCare (ASX:ICR) has had a successful first day of trading, with stocks sitting more than 50 per cent above their issue price, closing at 31.5 cents each.
While most companies aspiring to list on the ASX have faltered during the Coronavirus, telehealth company, InteliCare (ASX:ICR) has managed to get their listing away.